×
About 2,558 results

ALLMedicine™ Immuno-oncology Center

Research & Reviews  584 results

Mechanisms of T cell exhaustion guiding next-generation immunotherapy.
https://doi.org/10.1016/j.trecan.2022.04.004
Trends in Cancer; Zebley CC, Youngblood B

May 16th, 2022 - The functional decline in T cells during their chronic stimulation, commonly referred to as T cell exhaustion, is a major limitation for current immunotherapy approaches. As modern medicine embraces therapeutic approaches that exploit the immuno-o...

The TIOB - Collection of Patients' Biospecimens for Analysis of Immunological and Molecular Biomarkers.
https://clinicaltrials.gov/ct2/show/NCT05371756

May 12th, 2022 - The goal of establishing the Texas Immuno-Oncology Biorepository (TIOB) is to create a research facility that purposely consents patients to collect, catalog, process, store, and analyze biospecimens with well-annotated clinical/radiological data ...

Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer
https://clinicaltrials.gov/ct2/show/NCT04263051

May 11th, 2022 - Lung cancer is the most commonly diagnosed malignancy and the leading cause of cancer-related mortality both in men and women worldwide. The past few years have demonstrated great progress in the field of tumor immunotherapy through agents that ad...

Development of a LAG-3 immunohistochemistry assay for melanoma.
https://doi.org/10.1136/jclinpath-2022-208254
Journal of Clinical Pathology; Johnson L, McCune B et. al.

May 10th, 2022 - A robust immunohistochemistry (IHC) assay was developed to detect lymphocyte-activation gene 3 (LAG-3) expression by immune cells (ICs) in tumour tissues. LAG-3 is an immuno-oncology target with demonstrable clinical benefit, and there is a need f...

Data-rich spatial profiling of cancer tissue: Astronomy informs Pathology.
https://doi.org/10.1158/1078-0432.CCR-19-3748
Clinical Cancer Research : an Official Journal of the Ame... Szalay AS, Taube JM

May 7th, 2022 - Astronomy was among the first disciplines to embrace Big Data and use it to characterize spatial relationships between stars and galaxies. Today, medicine, in particular pathology, has similar needs with regard to characterizing the spatial relati...

see more →

Guidelines  1 results

Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Soc...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354771
Journal of Clinical Oncology : Official Journal of the Am... Tsimberidou AM, Levit LA et. al.

Oct 20th, 2018 - To develop recommendations for clinical trial reporting that address the unique efficacy, toxicity, and combination and sequencing aspects of immuno-oncology (IO) treatments. ASCO and the Society for Immunotherapy of Cancer (SITC) convened a worki...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  14 results

The TIOB - Collection of Patients' Biospecimens for Analysis of Immunological and Molecular Biomarkers.
https://clinicaltrials.gov/ct2/show/NCT05371756

May 12th, 2022 - The goal of establishing the Texas Immuno-Oncology Biorepository (TIOB) is to create a research facility that purposely consents patients to collect, catalog, process, store, and analyze biospecimens with well-annotated clinical/radiological data ...

Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer
https://clinicaltrials.gov/ct2/show/NCT04263051

May 11th, 2022 - Lung cancer is the most commonly diagnosed malignancy and the leading cause of cancer-related mortality both in men and women worldwide. The past few years have demonstrated great progress in the field of tumor immunotherapy through agents that ad...

Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
https://clinicaltrials.gov/ct2/show/NCT04589845

May 3rd, 2022 - TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectab...

Early Clinical Evaluation of 18F-LY3546117 in Tumor Imaging
https://clinicaltrials.gov/ct2/show/NCT04721756

Apr 25th, 2022 - Immuno-Oncology (IO) therapies have revolutionized cancer therapy and are becoming the standard of care for many cancers. Monitoring how well IO therapies work against cancer is difficult due to the complexity of the immune system and the fact tha...

Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
https://clinicaltrials.gov/ct2/show/NCT04242095

Apr 19th, 2022 - PRIMARY OBJECTIVES: To establish a national biorepository including biospecimen and clinical data collections from patients treated with immuno-oncology (IO) therapeutics who experience one or more serious (grade 3-4) immune-related adverse events...

see more →

News  421 results

New Class of Cancer Drugs Down, Not Out, After Roche Trial Setback: Analysts
https://www.medscape.com/viewarticle/973822

May 12th, 2022 - LONDON (Reuters) - The fresh blow to Roche's hopes in a closely watched class of cancer immunotherapies cast a long shadow across the crowded field on Wednesday, but the latest setback is not the end of the road for these oncology treatments, anal...

Recent Advances in Treatment of MET Exon 14 Skipping Mutations in NSCLC
https://www.onclive.com/view/recent-advances-in-treatment-of-met-exon-14-skipping-mutations-in-nsclc

May 5th, 2022 - Ben Levy, MD: Martin, let’s move on to MET exon 14 skipping mutations. Obviously, you get more approvals and options. It’s exciting. It’s sometimes difficult to identify MET exon 14 skipping mutations. Nevertheless, we’ve got 2 new drugs approved....

Interpreting Data From the ARASENS Trial in Metastatic HSPC
https://www.onclive.com/view/interpreting-data-from-the-arasens-trial-in-metastatic-hspc

May 2nd, 2022 - Transcript: Alicia Morgans, MD, MPH: Sandy, what are your thoughts are on the trial design, safety, and end points? Which of these is the most compelling to you? Or is there more than 1? What do you think is important about this study design that ...

Impact of Adjuvant Therapy on Treatment Selection in Advanced RCC
https://www.onclive.com/view/impact-of-adjuvant-therapy-on-treatment-selection-in-advanced-rcc

Apr 28th, 2022 - Tian Zhang, MD: Dr Braun, how has the use of adjuvant therapy has impacted our treatment decisions and subsequent therapy, specifically patients progressing after adjuvant pembrolizumab? David Braun, MD, PhD: That’s a great question. Truthfully...

FDA Grants Orphan Drug Designation to Toripalimab for Small Cell Lung Cancer
https://www.onclive.com/view/fda-grants-orphan-drug-designation-to-toripalimab-for-small-cell-lung-cancer

Apr 21st, 2022 - The FDA has granted an orphan drug designation to the PD-1 inhibitor toripalimab as a potential therapeutic option for patients with small cell lung cancer (SCLC), according to an announcement from Coherus BioSciences, Inc. and Shanghai Junshi Bio...

see more →